Sign In
Buy WGS
$63.85
-1.79 (-2.73%)
At Close: Jul 13, 2026
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 24'th Jan 2024
STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23, 2024
GeneDx Holdings stock climbs on upbeat 4Q guidance, profitability target
11:47am, Tuesday, 09'th Jan 2024
GeneDx Holdings Corp shares jumped 21% to $4.68 in late-morning trading on Tuesday after the provider of exome and genome testing and interpretation announced that it expects to exceed revised 2023 re
GeneDx Announces Preliminary 2023 Financial Results
08:55am, Monday, 08'th Jan 2024
Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations1 of more than $57M with at least 63% year-over-year revenue growth for exome and genome test
New research from one of the largest exome sequencing studies of patients with epilepsy adds to the mounting evidence that exome sequencing offers superior clinical results compared to multi-gene pane
GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
04:05pm, Tuesday, 28'th Nov 2023
STAMFORD, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 20'th Nov 2023
STAMFORD, Conn., Nov. 20, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of November 17, 202
Bears are Losing Control Over GeneDx Holdings Corp. (WGS), Here's Why It's a 'Buy' Now
11:16am, Friday, 10'th Nov 2023
After losing some value lately, a hammer chart pattern has been formed for GeneDx Holdings Corp. (WGS), indicating that the stock has found support. This, combined with an upward trend in earnings est
GeneDx Holdings Corp. (WGS) Q3 2023 Earnings Call Transcript
11:03am, Saturday, 04'th Nov 2023
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2023 Results Conference Call October 30, 2023 4:30 PM ET Company Participants Sabrina Dunbar - Chief of Staff Katherine Stueland - President and CEO Kevin Feeley
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
04:05pm, Monday, 09'th Oct 2023
STAMFORD, Conn., Oct. 09, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financia
GeneDx Holdings Corp. (WGS) Q2 2023 Earnings Call Transcript
03:50pm, Saturday, 12'th Aug 2023
GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2023 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Tricia Truehart - Head, IR Katherine Stueland - President and CEO Kevin Feeley - CFO
STAMFORD, Conn., June 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will present new data
GeneDx Holdings Corp. (WGS) Q1 2023 Earnings Call Transcript
11:02am, Sunday, 14'th May 2023
GeneDx Holdings Corp. (NASDAQ:WGS ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 AM ET Company Participants Tricia Truehart - Head Investor Relations Katherine Stueland - President & Chief Execut
Why GeneDx Holdings Stock Lagged the Market Today
06:39pm, Friday, 28'th Apr 2023
The genetic-testing specialist is effecting a reverse stock split. Although fully expected, this still wasn't encouraging news for shareholders.
GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
04:05pm, Tuesday, 18'th Apr 2023
STAMFORD, Conn., April 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financi
Why Shares of GeneDx Dropped Wednesday
04:36pm, Wednesday, 22'nd Mar 2023
GeneDx changed its name from Sema4 in January. The company focuses on genetic testing to better inform healthcare decisions.
